Nootropic Peptides: Where the Human Studies Actually Are

Nootropic peptides are sold on a promise that is hard to check and easy to feel: sharper focus, better recall, more mental stamina. Cognitive self-assessment is famously unreliable, which makes this the use case where personal testimony carries the least information and published evidence matters the most.

So this page does one thing: it says, for each compound, where the human studies are. For most of them the answer is somewhere unexpected.

Semax — a Literature Made of Rats

Semax is a synthetic analog of a fragment of ACTH, developed in Russia, and the most heavily marketed cognitive peptide.

Its published record is substantial. There is work on Semax regulating BDNF and TrkB expression in the rat hippocampus¹, on neurotrophin gene expression in rat brain², on nootropic and analgesic effects following different routes of administration³, on behavioral and neurochemical alterations in white rats⁴, and on how modifying the molecule changes its effects in animal models⁵.

Read that list again with attention to the species. The mechanistic story — BDNF, neurotrophins, the brain's own growth factors — is genuinely interesting, and it is the story every product page tells. What the product pages do not say is that it was established in rodents, and that a search for human cognitive trials of Semax does not return the confirmatory program you would expect after three decades.

That is the finding. Not "Semax is fake" — the animal work is real science. But a rat hippocampus is not a claim about your focus at work, and the gap between the two has not been closed by anyone in a way a reader can go and check.

Our compound-level assessments are in Semax vs Selank and Semax FDA status.

Selank — One Study, and It Was About Anxiety

Selank is Semax's stablemate from the same research tradition, and it is usually sold in the same breath for the same claimed benefits.

It does have a human clinical study, which is more than most of this category can say. But note what the study was: 62 patients with generalized anxiety disorder and neurasthenia, compared against a benzodiazepine, reported as similar in anxiolytic effect with additional antiasthenic and psychostimulant effects⁶. There was no placebo arm, it is published in Russian, and it has not been independently replicated.

So the one human trial in this family is an anxiety trial, not a cognitive-enhancement trial, and it carries the limitations we set out in detail in peptides for anxiety. Using it to support a focus-and-memory claim in healthy people is two steps beyond what it measured.

Cerebrolysin — the One That Got Real Scrutiny

Here is the compound worth knowing about, because it shows what actual evidence in this space looks like — and why it is not what you are being sold.

Cerebrolysin is a porcine brain-derived peptide preparation, described as having neurotrophic and neuroprotective activity, and given as a series of daily intravenous infusions⁷. In many parts of the world it is used as a potential intervention for vascular dementia.

It is the only compound in this category to have received the full apparatus of evidence-based medicine. There is a Cochrane systematic review of Cerebrolysin for vascular dementia, updated in 2019, which searched a dozen databases plus additional Chinese-language sources and contacted manufacturers and trial authors for unpublished data⁷. The review notes that the previous Cochrane review of Cerebrolysin in vascular dementia had yielded inconsistent results. There are also meta-analyses in mild-to-moderate Alzheimer's disease⁸ and randomized work in traumatic brain injury⁹.

Three things follow, and all of them matter for a reader shopping online.

First, that level of scrutiny is what a genuine cognitive claim attracts — a dozen databases, unpublished-data requests, formal appraisal of evidence strength. Nothing on a peptide menu has been through it.

Second, look at the population. Vascular dementia, Alzheimer's disease, traumatic brain injury — patients with an identified neurological condition. Not healthy adults seeking an edge. Evidence in an injured or diseased brain does not transfer to an intact one, and that is a substantive difference rather than a technicality.

Third, look at the delivery. Daily intravenous infusions, of a porcine brain extract, under supervision. That is not a vial and a syringe from a website.

The Delivery Problem Underneath All of It

A cognitive-enhancement peptide has to act on the brain, and a peptide injected under the skin has to cross the blood-brain barrier — a structure built specifically to exclude molecules of that kind.

Peptide transport across it is a real, well-studied field: some peptides cross by defined transport systems, many do not, and the rate matters as much as the fact¹⁰. This is a question to ask of each compound, and for most nootropic peptides sold online there is no published answer for that specific molecule. It is not a coincidence that Semax and Selank are typically sold as nasal sprays — intranasal delivery is an attempt to route around exactly this problem, and attempting it is not the same as having demonstrated it works.

The Measurement Problem

Cognitive enhancement is unusually vulnerable to self-deception, and it is worth being explicit about why.

You cannot observe your own cognition from outside. Attention feels different depending on sleep, caffeine, stress, mood, novelty and expectation, all of which move day to day. Starting something you researched, chose and paid for creates an expectation that reliably produces a felt improvement. And in a field mature enough to check — researchers have formally analyzed placebo responses in trials of intranasal peptides — the placebo component turns out to be large enough to require its own analysis.

This is why "I felt sharper within a week" cannot settle the question, however honestly reported. It is also why the absence of controlled human trials matters more here than almost anywhere else: the controlled trial exists precisely to separate the drug from the expectation, and nothing else does that job.

What Is Actually Priced, and Where

Cognitive peptides sit awkwardly in the market. The research-chemical vendors sell them by the vial with no clinical framing at all, and the prescriber menus that carry them treat them as general peptide inventory rather than cognitive products.

ElitePhysiqMD is the clearest example on our roster: eighteen priced peptides in one list, the cognitive and longevity compounds among them, epithalon at $233.10 and kisspeptin at $215.10, on a page whose homepage advertises the category "from $161/mo" — a floor no item on the menu actually meets. LaSara publishes a one-time price, a subscription price and a per-day cost on every product page, including a VIP nasal spray at $199 or $179 subscribed, which is the most transparent presentation we have recorded.

What neither offers, and what no seller in this category offers, is the thing that would justify the price: evidence that the compound does what the category name promises, in people who do not have a diagnosed neurological condition.

Boards and figures: the rankings index and the price transparency index.

What Is Sold, and the Quality Question

Nootropic peptides reach buyers mostly through research-chemical vendors rather than prescribers, which puts the quality question front and center: no approval pathway means no regulatory floor under identity, purity or sterility, and the dosing protocols circulated online came from forums rather than trials.

The checks are the same ones we apply everywhere — how to verify a COA, peptide vendor red flags, and what "research use only" means for who is accountable. Regulatory positions are tracked against the primary record in the peptide FDA status tracker, and the boards are indexed on the rankings index.

Bottom Line

For each compound, the honest answer to "where are the human studies?":

Semax — the published literature is overwhelmingly rodent: BDNF and TrkB in rat hippocampus, neurotrophin expression in rat brain, behavioral work in white rats¹²³⁴⁵. The mechanism is interesting and the human confirmation is not there to read.

Selank — one human trial, and it was an anxiety trial: 62 patients, no placebo arm, in Russian, not replicated⁶.

Cerebrolysin — the real scrutiny, and it belongs to a porcine brain extract given by daily IV infusion to patients with dementia or brain injury, assessed by a Cochrane review whose predecessor found inconsistent results⁷⁸⁹. Not a healthy-adult nootropic, and not something you buy online.

All of them — the blood-brain barrier question is unresolved for most specific compounds¹⁰, and self-assessment cannot substitute for a controlled trial in the one domain where self-assessment is least reliable.

For how each compound grades against human evidence rather than mechanism, see what are peptides good for, peptides for energy and the research library.